• Publications
  • Influence
Improved survival with MEK inhibition in BRAF-mutated melanoma.
BACKGROUND Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as comparedExpand
  • 1,189
  • 41
  • Open Access
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
BACKGROUND Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E orExpand
  • 1,077
  • 32
  • Open Access
Induced Pluripotent Stem Cells Generated Without Viral Integration
Pluripotent stem cells have been generated from mouse and human somatic cells by viral expression of the transcription factors Oct4, Sox2, Klf4, and c-Myc. A major limitation of this technology isExpand
  • 1,031
  • 28
  • Open Access
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells
The overexpression of defined transcription factors in somatic cells results in their reprogramming into induced pluripotent stem (iPS) cells. The extremely low efficiency and slow kinetics of inExpand
  • 794
  • 28
  • Open Access
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) have been derived at low frequencies from different cell types through ectopic expression of the transcription factors Oct4 and Sox2, combined with either Klf4Expand
  • 279
  • 16
  • Open Access
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
BACKGROUND Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of theExpand
  • 326
  • 15
  • Open Access
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
BACKGROUND Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma and other cancer entities. They act via blockade of the PD-1 receptor, anExpand
  • 277
  • 13
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Abstract Background Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versusExpand
  • 235
  • 10
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Under steady-state conditions, bone marrow-derived immature myeloid cells (IMC) differentiate into granulocytes, macrophages and dendritic cells (DCs). This differentiation is impaired under chronicExpand
  • 69
  • 10
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as comparedExpand
  • 1,166
  • 8